Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biophan Technologies has said that Myotech, the company's majority-owned subsidiary, has entered into a memorandum of understanding with PPA Technologies to explore the potential for a strategic relationship regarding the development and commercialization of their respective technologies.
Subscribe to our email newsletter
PPA Technologies is developing a technical solution for active support in cases of cardiac insufficiency and complete temporary support during cardiac arrest. This technology could be complementary to the Myotech Circulatory Support System (CSS), which is intended to improve the treatment of acute heart failure.
John Lanzafame, Biophan’s CEO, said: “We have entered into this agreement to explore the potential for collaboration between the two companies, to strengthen our product offerings and infrastructure.”